ELSEVIER

CLINICAL/ORIGINAL PAPERS

Myocardial stiffness and the timing difference between tissue Doppler imaging Ea and peak mitral valve opening can distinguish physiological hypertrophy in athletes from hypertrophic cardiomyopathy

Gerard King [a],*, Jerome Brendan Foley [a], Colin Forbes Royse [b], Konstantin Yastrebov [c], Matthew Hussey [d], Gerard Boyle [e], Kathleen Bennet [f], John Cosgrave [a], Peter Crean [a], Michael Walsh [a]

[a] Cardiology Department, St James Hospital, Dublin 8, Ireland
[b] Cardiovascular Therapeutics Unit, Department of Pharmacology, University of Melbourne, Australia
[c] University of Tasmania, and Tasmanian Institute of Critical Care, Davenport, Tasmania, Australia
[d] Dublin Institute of Technology, Kevin Street, Dublin, Ireland
[e] Medical Physics Department, St James Hospital, Dublin 8, Ireland
[f] Department of Pharmacology and Therapeutics, St James Hospital, Dublin 8, Ireland

Abstract *Aim:* To differentiate between physiological and pathological left ventricular hypertrophy in athletes using echocardiography.
Methods and results: Eleven patients with mild hypertrophic cardiomyopathy were compared against 17 international rowers with mild left ventricular hypertrophy, and 30 age matched controls. The time difference between peak Ea (Doppler tissue imaging) and peak mitral valve opening (using M-mode) was measured simultaneously. A novel index (E/Ea)/LVEDD, as a measure of left ventricular stiffness was recorded. In athletes the peak Ea preceded peak mitral opening by: median (interquartile range) 20 ms (10,20), control group 15 ms (0,30), compared with HCM where Ea followed peak mitral opening by 10 ms (0,20), $P < 0.0001$. In athletes the index of left ventricular stiffness was lower than controls 1.2 (0.93,1.4) versus 1.5 (1.3,1.6), and HCM 2.2 (2.0,2.3), $P < 0.0001$.

* Corresponding author. Tel.: +353 1 416 2792; fax: +353 1 410 3467.
 E-mail address: gking@stjames.ie (G. King).

Conclusion: Physiological hypertrophy can be differentiated from hypertrophic cardiomyopathy in athletes using the Ea-peak mitral opening difference, and our index of ventricular stiffness.

Introduction

Sudden death in athletes is a sporting catastrophe.[1] Identifying athletes at risk of sudden death remains a great challenge because the athlete's heart undergoes adaptive changes in response to physical exercise that can induce left ventricular hypertrophy (LVH) that can mimic pathological abnormalities.[2] The more important question that needs to be resolved once an athlete is identified as having LVH is whether it is a normal physiological response or a pathological phenomenon, with hypertrophic cardiomyopathy being the important differential diagnosis. Methods are currently employed to diagnose whether athletes have physiological or pathological left ventricular hypertrophy (LVH),[3] but they are not comprehensive or practical for large populations. Genetic studies in the past have revealed that a substantial minority of patients with HCM have LVH in the same range as athletes, but genetic testing is not a practical option.[3] Traditional echocardiographic and electrocardiographic features may not adequately distinguish physiological from pathological LVH.[1]

Doppler Tissue Imaging (DTI) is an ultrasound modality that can be used to record systolic and diastolic myocardial velocities.[4,5] Studies have recorded mitral annular displacement and velocity both in systole and diastole as indicators of overall cardiac performance.[6−8] Our aims were to evaluate novel indices using DTI and other echocardiography modalities to differentiate hypertrophic cardiomyopathy (HCM) from athletic physiological left ventricular hypertrophy where mild LVH exists.

Methods

Following approval from the human ethics committee of the St James Hospital, patients and volunteers were recruited and informed written consent obtained.

Between 2002 and 2004 ongoing research of 27 patients diagnosed with HCM (HCM group) led to the identification of 11 (30%) adults with characteristics of mild HCM (LV wall thickness >13 mm) without left ventricular outflow tract obstruction. Routine genetic testing was not available at the time of recruitment for our study. The patients were recruited from our out-patient department with a clinical diagnosis of HCM based on clinical presentation (chest pain, dyspnoea, syncope, family history of HCM or sudden death), examination findings and the presence of significant LVH in the absence of an identifiable cause of the LVH. Six had a history of arrhythmia and abnormal ECG (of which three had increased voltages with prominent q waves and the other three had inverted t waves with prominent q waves). The other five had normal ECG, but had a strong family history of HCM, arrhythmias, dyspnoea, and serial echoes over previous years showed progressive left ventricular wall thickness.

The physiological LVH group was identified among 34 highly trained international rowers who had trained intensively 15−20 h per week for more than 5 years, of which 17 (50%) had a left ventricular wall thickness ≥12 mm. None had a family history of HCM or premature sudden cardiac death, and all were normotensive. A control group of 30 sedentary but otherwise normal subjects were recruited from hospital personnel including young hospital doctors and medical students.

Measurement protocol

Echocardiography images were obtained with Philips Sonos 5500 and Philips Sonos 4500 cardiac ultrasound systems (Phillips, Andover, USA).

1. Baseline echocardiography examination to rule out structural abnormality.
2. Doppler tissue imaging recordings were obtained from the apical views at the medial, lateral, inferior, and anterior basal segments just below the mitral annulus. The average velocity from the four sites was calculated.
3. Mitral inflow pulsed wave Doppler spectral display.
4. Left ventricular end-diastolic dimension (LVEDD), and septal and posterior wall thicknesses were obtained from the parasternal long axis view, with the M-mode cursor cutting through the base of the heart. Ejection fraction was calculated by the method of disc summation based on Simpson's rule. This method treats the ventricle as a stack of discs and is

recommended because it is independent of preconceived ventricular shape. Left ventricular mass was estimated by the method of Devereux by applying the Penn convention.[9]

5. Time delay between peak tissue annular velocity (Ea) and peak mitral valve opening was calculated by obtaining simultaneous M-mode recording of mitral valve opening and lateral annular DTI using two echocardiography machines and a sharply defined time referenced pulse. The reference pulse was introduced into unused ECG channels on both machines by pressing a foot switch activated circuits, which allowed comparisons to be made in the same heartbeat. This relationship is shown in Fig. 1.

A sweep speed of 100 mm/s was used for all recordings. Measurements were performed offline by two independent observers, blinded to each other's data. The values presented are the average of both observers with three beats per measurement.

Derived indices

1. Time difference between peak Ea and peak (maximal) mitral valve opening.
2. Index of end-diastolic stiffness: E/Ea can be used to estimate left atrial pressure[8] and LVEDD can be used to estimate left ventricular end-diastolic volume. The ratio (E/Ea)/LVEDD is an estimate of end-diastolic stiffness.

Statistical methods

Results are presented as mean ± standard deviations (SD) for continuous variables, and medians with interquartile ranges (IQR) for ratios and for the timing difference. For comparisons between all groups, one-way analysis of variance or non-parametric Kruskal—Wallis test was used where appropriate. Pairwise comparisons between athletes and controls, and athletes and HCMs were made using Tukey—Kramer HSD test for multiple comparisons or non-parametric Wilcoxon rank sum test where appropriate. Inter-observer variability was examined for Ea and time difference using the method of Bland and Altman.[10] All analyses were performed using the JMP statistical analysis package (SAS Inst. Inc). A P value <0.05 was considered statistically significant.

Results

There were no significant differences in group demographic details (shown in Table 1).

In athletes the peak Ea preceded peak mitral opening by: median (interquartile range) 20 ms

Figure 1 Timing relationship between peak Ea and peak mitral valve opening. A time reference pulse was introduced into the displays of both machines to allow measurement on simultaneous heartbeats. In physiological LVH, the peak Ea preceded the peak MV opening, whereas in HCM, the peak Ea followed the peak MV opening.

Table 1 Study participant's demographic details

	HCM ($N = 11$)	Athlete ($N = 17$)	Control ($N = 30$)	P
Age (years)[a]	31 (13,40)	28 (24,30.5)	26 (24,28)	0.20
Men/women	9/2	14/3	25/5	0.05
Heart rate[b] (bpm)	67.4 ± 5.1	65 ± 10.7	70.0 ± 5.1	<0.001
Body surface area (m^2)[a]	1.93 (1.91,2.0)	2.0 (1.95,2.1)	1.84 (1.6,1.9)	<0.001

HCM, athlete and control are hypertrophic cardiomyopathy, athlete, and normal control groups, respectively.
[a] Median and IQR presented for non-normal data.
[b] Mean $\pm$ SD.

(10,20), control group 15 ms (0,30), compared with HCM where Ea followed peak mitral opening by 10 ms (0,20), $P < 0.0001$ (Fig. 2).

Echocardiography data for the three groups are shown in Table 2. Athletes had significantly higher values than in controls for left atrial dimension, septal and posterior wall thicknesses, LVEDD and LVESD, LV mass index, and Ea. The HCM group had higher values than athletes for deceleration time, E/Ea, and the index of myocardial stiffness. The HCM group had significantly lower values than athletes for LVEDD, LVESD, E/A ratio, Ea, and DTI systolic velocity. The index of myocardial stiffness is shown for all groups in Fig. 3.

The percentage of study participants for each group who had peak Ea delayed after peak mitral opening by ≥ 0 ms, and who had (E/Ea)/LVEDD value ≥ 1.7 is shown in Table 3.

Using the method of Bland and Altman,[10] the correlation $r = 0.0097$ ($p = 0.622$), for reproducibility for each four-site average, and $r = 0.061$ ($p = 0.758$) for the time difference were found. The correlations are close to 0 and therefore this

Figure 2 Box and whisker plot of the time difference between peak Ea and peak mitral valve opening (ms) for control, athlete and HCM groups (box represents IQR and solid line within the box the median, whiskers represent the range of values).

suggests that there is negligible inter-observer bias in the measurements.

Discussion

Our study shows that the key distinguishing feature of pathological versus physiological LVH is the presence of diastolic dysfunction. Measures of systolic function such as ejection fraction were not different between groups,[11] and although the systolic DTI wave was lower in HCM, it was within normal values.[12] The LVEDD in athletes was larger than that in other groups and is consistent with values at the upper limit of normal or mildly dilated,[13] but with preserved ejection fraction. Of the measurements of diastolic function, the mitral in-flow Doppler and isovolumic relaxation times are within normal values, though deceleration time for HCM was at the upper limit of normality.[14–17] The American Heart Association recommends Ea as the best measure of diastolic function in clinical trials,[18] but fails to recommend normal values. Studies by Ho et al.[19] and Nagueh et al.[20] suggest that DTI can be used to identify a group of individuals with HCM with or without the presence of LVH. This is consistent with our findings that Ea was significantly lower in the HCM group, but the problem lies in the definition of threshold values for delineating diastolic dysfunction from normal. Garcia et al.[17] recommend threshold values of 10 cm/s for young people and 8 cm/s for normal adults. This places the values for our HCM group as normal or just subnormal depending on age. If the threshold was raised to 12.5 cm/s as suggested by Dumesnil et al.[21] then Ea alone could identify pathological LVH.

We report two non-invasive measurements using Doppler tissue imaging and other echocardiography modalities which can help to differentiate pathological LVH from athletic physiological hypertrophy. Diastolic stiffness is assessed by the pressure/volume relationship (E/Ea)/LVEDD. In athletes, the LVEDD is larger than controls, but

Table 2 Echocardiography data of study participants

	HCM	Athlete	Control	P
Left atrial diameter (mm)[a]	4.0 ± 0.4	3.8 ± 0.4[c]	3.5 ± 0.4	0.002
Septal wall thickness (mm)[b]	1.4 ± 0.1	1.3 ± 0.1[c]	0.89 ± 0.2	<0.001
Posterior wall thickness[b]	1.3 ± 0.06	1.3 ± 0.1[c]	1.0 ± 0.2	<0.001
LVEDD (mm)[b]	4.6 ± 0.2[d]	5.6 ± 0.1[c]	4.8 ± 0.4	<0.001
LVESD (mm)[b]	3.0 ± 0.5[d]	3.6 ± 0.6[c]	3.1 ± 0.5	0.015
Ejection fraction (%)[b]	67 ± 5	64 ± 5	64 ± 5	0.164
Left ventricular mass index (g/m^2)[b]	167.0 ± 22.4	187.9 ± 24.3[c]	101.96 ± 27.0	<0.001
Mitral E wave (cm/s)[a]	59.3 (45,72)	65.5 (59.1,81.2)	72.8 (62,86.3)	0.034
Mitral A wave (cm/s)[a]	40.5 (21.75,70.3)	36.5 (32.8,47.9)	40 (34.5,48.7)	0.940
E/A ratio[a]	1.2 (0.6,1.5)[d]	1.7 (1.5,2.0)	1.7 (1.5,2.0)	0.001
IVRT[b]	92.7 ± 15.6	82.0 ± 11.6	75.3 ± 9.8	0.014
Mitral E deceleration time[b]	223 ± 69[d]	185 ± 40	169 ± 39	0.004
Ea averaged 4 site velocity (cm/s)	8.2 ± 1.5[d]	19.2 ± 2.2[c]	17.9 ± 3.0	<0.001
E/Ea[b]	9.8 (7.9,12.5)[d]	6.6 (5.4,7.5)	7.1 (6.5,7.7)	0.002
Systolic wave velocity (cm/s)[b]	8.7 ± 2.5 ^{2}	12.2 ± 1.6	10.3 ± 1.4	<0.001
New index of myocardial stiffness (E/Ea)/LVEDD[a]	2.2 (1.9,2.3)[d]	1.2 (0.9,1.4)[c]	1.5 (1.3,1.6)	<0.001

[a] Median and IQR presented for ratios and time differences, P = Kruskal−Wallis test between groups.
[b] Mean ± SD # adjusted for age and gender, or ANOVA between groups where appropriate.
[c] Multiple comparison test, $P < 0.05$ for comparison of athletes to controls.
[d] Multiple comparison test, $P < 0.05$ for comparison of athletes to HCM.

at normal E/Ea, indicating a compliant ventricle. Conversely, patients with HCM exhibit normal LVEDD, but with a higher E/Ea ratio indicating reduced compliance (increased stiffness).

Our second method is to compare the timing relationship between peak Ea and peak mitral valve opening, which seeks to identify whether the myocardium moves prior to opening of the mitral valve, or whether it follows it. When Ea precedes MV opening, it suggests continued expansion of the LV prior to MV opening, and that MV opening is initiated by LV ''suction'' (pulling the MV open)


Figure 3 Box and whisker plot of the index of myocardial stiffness (E/Ea)/LVEDD is shown for control, athlete and HCM groups (box represents IQR and solid line within the box the median, whiskers represent the range of values).

causing a lower intracavity pressure than left atrial pressure. Conversely, if the MV opens prior to Ea, then it suggests that the continued relaxation of the LV is delayed, and MV opening is initiated by the left atrial pressure exceeding intracavity pressure (pushing the MV open). In normal volunteers and athletes, the peak Ea preceded the peak MV opening, whereas in HCM, the peak MV opening preceded the peak Ea. Importantly, there was clear separation in results between athletes with LVH and patients with HCM. Although our data cannot identify the mechanism of continued LV relaxation, our findings are consistent with preserved elastic recoil in normal hearts, whereas the complex genetic mutations of HCM lead to a loss of elastic recoil and diastolic impairment.

We have previously demonstrated that mitral diastolic peak annular tissue velocity occurs earlier than the peak of the early mitral inflow velocity in normal human hearts versus patients with diastolic dysfunction.[22] Our findings of altered timing between peak tissue velocity (Ea) and peak mitral (E) valve opening on M-mode are similar to those reported by Rodriguez et al.[23] who investigated this relationship in patients with LVH. Patients with

Table 3 Percentage of participants with abnormal measurements

	HCM	Athletes	Control
Peak Ea delayed after peak MV opening by ≥0 ms	100	0	23.3
(E/Ea)/LVEDD ≥1.7	73	5.9	13.3

LVH showed a delay in peak early diastolic mitral annular velocity (21 ms $\pm$ 5.5 ms, $P = 0.002$, after the E wave), whereas in patients without heart disease the onset of mitral flow and diastolic annular motion were simultaneous, but the peak annular velocity preceded the peak mitral M-mode E by an average of 20 ms. In the study by Rodriguez et al.,[23] M-mode and DTI measurements were measured on different heartbeats, with times of the peak velocities referred to the ECG R-wave. In our study M-mode and DTI measurements were taken simultaneously and time differences measured are actual time differences between events in a single heartbeat. The timing method is not clinically practical as it requires two echo machines, but future technological innovation to allow the simultaneous overlay of M-mode or conventional Doppler with DTI spectra using one ultrasound system will improve the ease and reliability of the timing technique, although it may be reasonable to use different heartbeats (one machine) timed to the R-wave to determine whether peak Ea precedes or follows peak MV opening.

There are several limitations to our study. The group sizes were relatively small due to the low prevalence of LVH in athletes. The number of patients with clinically proven mild HCM and LVH that is in the same range associated with physiological hypertrophy is also small. We also only included international level athletes and so we cannot directly attribute our findings to recreational athletes. Additionally, although we recruited ''normal'' controls, we did not have any guarantee that they did not have subtle underlying dysfunction. There was overlap in the timing difference and ventricular stiffness measurements between normals and HCM, which could indicate that some of the normal patients may have early diastolic dysfunction rather than an insensitivity of the measurements. There was a trend that HCM patients were older, though we excluded patients older than 55 years to reduce this effect. The technical limitations with regard to time resolution of the ultrasound systems did not allow us to measure time differences below 5 ms. With further technical advances we would expect to see an improvement in this time resolution in ultrasound systems. Although we have demonstrated a difference in myocardial stiffness, we do have sufficient data to present ''normal values'' for wide range ages, or the effect if any of gender.

Conclusion

Pathological LVH can be differentiated from physiological LVH by the presence of increased LV stiffness, and by the reversal of the normal diastolic timing between peak Ea and peak MV opening.

Acknowledgements

References

1. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. *J Am Med Assoc* July 17, 1996;**276**(3):199—204.
2. Spirito P, Pelliccia A, Proschan MA, Granata M, Spataro A, Bellone P, et al. Morphology of the ''athlete's heart'' assessed by echocardiography in 947 elite athletes representing 27 sports. *Am J Cardiol* Oct 15, 1994;**74**(8):802—6.
3. Fananapazir L, Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. *Circulation* Aug 15, 1995;**92**(4):700—4.
4. McDicken WN, Sutherland GR, Moran CM, Gordon LN. Colour Doppler velocity imaging of the myocardium. *Ultrasound Med Biol* 1992;**18**(6—7):651—4.
5. Erbel R, Wallbridge DR, Zamorano J, Drozdz J, Nesser HJ. Tissue Doppler echocardiography. *Heart* Sep 1996;**76**(3):193—6.
6. Galiuto L, Ignone G, DeMaria AN. Contraction and relaxation velocities of the normal left ventricle using pulsed-wave tissue Doppler echocardiography. *Am J Cardiol* Mar 1, 1998;**81**(5):609—14.
7. Fukuda K, Oki T, Tabata T, Iuchi A, Ito S. Regional left ventricular wall motion abnormalities in myocardial infarction and mitral annular descent velocities studied with pulsed tissue Doppler imaging. *J Am Soc Echocardiogr* Sep 1998;**11**(9):841—8.
8. Nagueh SF, Lakkis NM, Middleton KJ, Spencer 3rd WH, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. *Circulation* Jan 19 1999;**99**(2):254—61.
9. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. *Hypertension* Feb 1987;**9**(2 Pt 2):II9—26.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* Feb 8, 1986;**1**(8476):307—10.
11. Pfisterer ME, Battler A, Zaret BL. Range of normal values for left and right ventricular ejection fraction at rest and during exercise assessed by radionuclide angiocardiography. *Eur Heart J* Aug 1985;**6**(8):647—55.
12. Sun JP, Popovic ZB, Greenberg NL, Xu XF, Asher CR, Stewart WJ, et al. Noninvasive quantification of regional myocardial function using Doppler-derived velocity, displacement, strain rate, and strain in healthy volunteers: effects of aging. *J Am Soc Echocardiogr* Feb 2004;**17**(2):132—8.
13. Salton CJ, Chuang ML, O'Donnell CJ, Kupka MJ, Larson MG, Kissinger KV, et al. Gender differences and normal left ventricular anatomy in an adult population free of

hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. *J Am Coll Cardiol* Mar 20, 2002;**39**(6):1055—60.

14. Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. *J Am Coll Cardiol* Jun 1996; **27**(7):1753—60.

15. Rakowski H, Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J, et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. *J Am Soc Echocardiogr* Sep—Oct 1996;**9**(5):736—60.

16. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. *J Am Soc Echocardiogr* Apr 1997;**10**(3): 246—70.

17. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. *J Am Coll Cardiol* Oct 1998;**32**(4):865—75.

18. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. *J Am Soc Echocardiogr* Oct 2004;**17**(10):1086—119.

19. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. *Circulation* June 25, 2002; **105**(25):2992—7.

20. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. *Circulation* July 10, 2001;**104**(2):128—30.

21. Dumesnil JG, Paulin C, Pibarot P, Coulombe D, Arsenault M. Mitral annulus velocities by Doppler tissue imaging: practical implications with regard to preload alterations, sample position, and normal values. *J Am Soc Echocardiogr* Oct 2002;**15**(10 Pt 2):1226—31.

22. King GJ, Foley JB, Almane F, Crean PA, Walsh MJ. Early diastolic filling dynamics in diastolic dysfunction. *Cardiovasc Ultrasound* July 25, 2003;**1**(1):9.

23. Rodriguez L, Garcia M, Ares M, Griffin BP, Nakatani S, Thomas JD. Assessment of mitral annular dynamics during diastole by Doppler tissue imaging: comparison with mitral Doppler inflow in subjects without heart disease and in patients with left ventricular hypertrophy. *Am Heart J* May 1996;**131**(5):982—7.